The Low DoseThe GLP-1 price desk
Briefing

Lemonaid Health vs Ro

$348/mo against $448/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. Lemonaid Health costs $348 a month and Ro costs $448, a difference of $100 a month or about $1,200 a year. The desk reads it as follows.

Lemonaid Health is established platform with multi-month discounts. Ro is branded medication with insurance help. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. Lemonaid Health advertises $229 and bills $348; Ro advertises $149 and bills $448. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

LemonaidRo
Advertised$229$149
Billed$348$448
Gap+$119+$299
Per year, billed$4,176$5,376

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

2 differences on the record. The others match.

LemonaidRo
Will pursue insurance coverageNoYes
Can dispense FDA-approved branded medicationNoYes

What each puts on the record: Lemonaid Health

  • A compounded tirzepatide microdose tier is listed at $199/month.
  • Medication is billed separately from the membership.

Where it wins: Multi-month plans cut the medication price substantially. Watch for: Add $49/month to every price you are quoted. The advertised $129 is a programme floor, not the injection cost.

What each puts on the record: Ro

  • Effective all-in cost commonly lands between $298 and $598/month depending on the medication and any insurance coverage.
  • Cancellation requires notice before the renewal date.

Where it wins: FDA-approved medication only, which removes the compounding-regulation question entirely. Watch for: The membership and the medication are two separate bills. A $39 first month does not mean a $39 prescription.

In each one’s favour

Lemonaid Health.

  • Multi-month plans cut the medication price substantially.
  • An established platform with a long operating history in telehealth.

Ro.

  • FDA-approved medication only, which removes the compounding-regulation question entirely.
  • Genuine help pursuing insurance coverage.

Lemonaid Health scores higher overall at 3.5 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

The desk’s call

The board says Lemonaid Health. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

The verdict

On the board, Lemonaid Health at $348 a month is the more defensible choice on arithmetic alone. Ro earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: Lemonaid Health and Ro.

How they sit against everyone else

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none—
Ozari Health$125$125none—
Fifty 410$133$133none+$8/mo

More from the desk

  • Lemonaid Health tirzepatide review

    Advertised at $229, billed at $348. Position 12 of 18 on our board.

  • Ro tirzepatide review

    Advertised at $149, billed at $448. Position 17 of 18 on our board.

  • How to spot a bad seller

    The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

  • The twelve-month cost

    Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure